董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Erin S. Enright | 女 | Chairman of the Board | 62 | 3.00万美元 | 未持股 | 2023-10-24 |
| Scott A. Klosterman | 男 | Independent Director | 65 | 3.00万美元 | 未持股 | 2023-10-24 |
| Brian D. Baker | 男 | Director, President and Chief Executive Officer | 56 | 28.23万美元 | 未持股 | 2023-10-24 |
| David B. Holtz | 男 | Director | 57 | 3.00万美元 | 未持股 | 2023-10-24 |
| Brian M. Larkin | 男 | Director | 54 | 2.00万美元 | 未持股 | 2023-10-24 |
| R. Scott Ward | 男 | Independent Director | 67 | 2.00万美元 | 未持股 | 2023-10-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Brian D. Baker | 男 | Director, President and Chief Executive Officer | 56 | 28.23万美元 | 未持股 | 2023-10-24 |
| John Krier | 男 | Interim Chief Financial Officer | 46 | 38.68万美元 | 未持股 | 2023-10-24 |
董事简历
中英对照 | 中文 | 英文- Erin S. Enright
-
Erin S. Enright，她是Lee Medical（新泽西普兰斯堡的骨髓针供应商）的总裁和Prettybrook Partners, LLC（私人投资公司 ）的管理成员。从2010年到2013年，她曾在Ceelite Technologies, LLC董事会任职。从2005年到2007年，她担任InfuSystem, Inc.的首席财务官。从1993年到2003年，她担任Citigroup的股权资本市场部门董事总经理。她与其他个人和公司货其他子公司之间没有任何安排，据此她被选作为公司的董事。她与任何董事、执行官或个人提名或公司选择的成为董事或执行官的人之间没有家庭关系。而且她和她的直系亲属和公司或任何子公司之间没有任何交易。
Erin S. Enright,currently serves as a Managing Member of Prettybrook Partners LLC, a family office dedicated to investing in healthcare companies. Prettybrook has approximately 20 active investments in a variety of companies, typically as a co-investor with institutional private equity. In addition to her service as Chairman, Ms. Enright is Chairman of the Nominating and Governance Committee and a member of the Audit Committee and Compensation Committee of the Board. She is a member of the Board of Directors and Chair of the Nominating/Governance and Compensation Committee of Medical Facilities Corporation (TSX: DR), and a member of the Board of Directors and Chair of the Audit Committee of Keystone Dental, Inc., a private company controlled by the private equity firm Accelmed. Previously, she was on the Board of Directors and Chair of the Audit Committee of Amarin Corporation, plc (NASDAQ: AMRN) from 2022-23, on the Board of Directors and Chair of the Audit Committee of Brooklyn ImmunoTherapeutics, Inc. (NASDAQ: BTX) during 2022, and on the Board of Directors and Audit Committee of Biolase, Inc. (NASDAQ: BIOL) during 2013. She was a also member of the Board of Directors of Tigerlabs, a Princeton-based business accelerator, from 2012 to 2018, and from 2010 to 2015 served on the Board of Directors of Ceelite Technologies, LLC. She was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004-2013. She was Chief Financial Officer of InfuSystem, Inc. (NASDAQ: INFU) from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, where she was a Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm's Institutional Investors Committee, responsible for screening and approving the firm's participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm's underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm's New York office. Ms. Enright received her A.B. degree from the School of Public and International Affairs at Princeton University and J.D. degree from the University of Chicago Law School. - Erin S. Enright，她是Lee Medical（新泽西普兰斯堡的骨髓针供应商）的总裁和Prettybrook Partners, LLC（私人投资公司 ）的管理成员。从2010年到2013年，她曾在Ceelite Technologies, LLC董事会任职。从2005年到2007年，她担任InfuSystem, Inc.的首席财务官。从1993年到2003年，她担任Citigroup的股权资本市场部门董事总经理。她与其他个人和公司货其他子公司之间没有任何安排，据此她被选作为公司的董事。她与任何董事、执行官或个人提名或公司选择的成为董事或执行官的人之间没有家庭关系。而且她和她的直系亲属和公司或任何子公司之间没有任何交易。
- Erin S. Enright,currently serves as a Managing Member of Prettybrook Partners LLC, a family office dedicated to investing in healthcare companies. Prettybrook has approximately 20 active investments in a variety of companies, typically as a co-investor with institutional private equity. In addition to her service as Chairman, Ms. Enright is Chairman of the Nominating and Governance Committee and a member of the Audit Committee and Compensation Committee of the Board. She is a member of the Board of Directors and Chair of the Nominating/Governance and Compensation Committee of Medical Facilities Corporation (TSX: DR), and a member of the Board of Directors and Chair of the Audit Committee of Keystone Dental, Inc., a private company controlled by the private equity firm Accelmed. Previously, she was on the Board of Directors and Chair of the Audit Committee of Amarin Corporation, plc (NASDAQ: AMRN) from 2022-23, on the Board of Directors and Chair of the Audit Committee of Brooklyn ImmunoTherapeutics, Inc. (NASDAQ: BTX) during 2022, and on the Board of Directors and Audit Committee of Biolase, Inc. (NASDAQ: BIOL) during 2013. She was a also member of the Board of Directors of Tigerlabs, a Princeton-based business accelerator, from 2012 to 2018, and from 2010 to 2015 served on the Board of Directors of Ceelite Technologies, LLC. She was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004-2013. She was Chief Financial Officer of InfuSystem, Inc. (NASDAQ: INFU) from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, where she was a Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm's Institutional Investors Committee, responsible for screening and approving the firm's participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm's underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm's New York office. Ms. Enright received her A.B. degree from the School of Public and International Affairs at Princeton University and J.D. degree from the University of Chicago Law School.
- Scott A. Klosterman
-
Scott A. Klosterman曾担任Hanger, Inc. NYSE：HGR（一家假体、矫正治疗解决办法的领先供应商）术后产品部副总裁和总经理。2009年到2010年担任田纳西州查特怒加市执行顾问，为健康医疗业务提供咨询服务，帮助他们改进产品开发过程和成功地推出新产品。Klosterman从2003年到2008年担任Chattanooga Group（DJO, Inc.一个分部，由田纳西州查特怒加市Blackstone Group持有）分部总裁；之前于1997年到2003年担任首席运营官；1994年到1997年担任首席财务官和秘书。Klosterman持有Baylor University 工商管理硕士学位以及the University of Delaware会计（最高荣誉）理学学士学位。
Scott A. Klosterman,is Chief of Staff at HNI Healthcare, a technology-enabled physician management company, since April 2020 where he previously served as Chief Financial Officer (2018-2020) and Executive Vice President of Financial Operations (2016-2017). From 2010 to 2015, he was Vice President and General Manager, Post-Operative Products and Services at Hanger, Inc., a leading provider of prosthetic, orthotic, and therapeutic solutions. From 2009 to 2010, he was an executive consultant, providing consulting services to healthcare businesses, advising on product development and new product launches. He was Division President of Chattanooga Group from 2003 to 2008, where he previously served as Chief Operating Officer (1997-2003) and Chief Financial Officer, Secretary, and Treasurer (1994-1997). He was a licensed certified public accountant in Pennsylvania from 1982 until 1994 and has an M.B.A. degree from Baylor University and a B.S. degree in Accounting (with highest honors) from the University of Delaware. - Scott A. Klosterman曾担任Hanger, Inc. NYSE：HGR（一家假体、矫正治疗解决办法的领先供应商）术后产品部副总裁和总经理。2009年到2010年担任田纳西州查特怒加市执行顾问，为健康医疗业务提供咨询服务，帮助他们改进产品开发过程和成功地推出新产品。Klosterman从2003年到2008年担任Chattanooga Group（DJO, Inc.一个分部，由田纳西州查特怒加市Blackstone Group持有）分部总裁；之前于1997年到2003年担任首席运营官；1994年到1997年担任首席财务官和秘书。Klosterman持有Baylor University 工商管理硕士学位以及the University of Delaware会计（最高荣誉）理学学士学位。
- Scott A. Klosterman,is Chief of Staff at HNI Healthcare, a technology-enabled physician management company, since April 2020 where he previously served as Chief Financial Officer (2018-2020) and Executive Vice President of Financial Operations (2016-2017). From 2010 to 2015, he was Vice President and General Manager, Post-Operative Products and Services at Hanger, Inc., a leading provider of prosthetic, orthotic, and therapeutic solutions. From 2009 to 2010, he was an executive consultant, providing consulting services to healthcare businesses, advising on product development and new product launches. He was Division President of Chattanooga Group from 2003 to 2008, where he previously served as Chief Operating Officer (1997-2003) and Chief Financial Officer, Secretary, and Treasurer (1994-1997). He was a licensed certified public accountant in Pennsylvania from 1982 until 1994 and has an M.B.A. degree from Baylor University and a B.S. degree in Accounting (with highest honors) from the University of Delaware.
- Brian D. Baker
-
Brian D. Baker于2022年1月重新加入Dynatronics Corporation，担任首席运营官。Baker先生于2019年8月至2020年7月担任Dynatronics Corporation首席执行官，并于2019年5月至2019年8月担任Dynatronics Corporation首席运营官。因与新冠肺炎病毒相关的健康问题，Baker先生辞去首席执行官一职后，继续担任公司雇员至2020年10月8日，随后担任公司顾问和董事会成员，至2022年1月重新全职加入Dynatronics Corporation。2018年2月至2019年5月，Baker先生担任Dynatronics Corporation治疗产品部总裁。在加入Dynatronics之前，他于2015年7月至2018年1月担任SeaSpine控股公司全球运营副总裁，于2015年3月至2015年7月担任Integra LifeSciences公司Seaspine业务运营副总裁。2013年11月至2015年3月，他担任行业顾问，提供并购和业务流程优化服务。他拥有凤凰城大学商学学士学位。
Brian D. Baker,was recently appointed as Chief Executive Officer effective October 1, 2023 and as President in May 2023. Mr. Baker first joined the Company as President of Therapy Products in February 2018. He served as Chief Operating Officer from May 2019 until his promotion to Chief Executive Officer in August 2019. Mr. Baker held that position until July 2020, when he resigned due to health issues relating to the COVID-19 virus. Following his resignation as Chief Executive Officer, Mr. Baker continued as a member of the Board and a consultant to the Company until his appointment as Chief Operating Officer in January 2022. Prior to joining the Company, Mr. Baker was Vice President of Global Operations of Seaspine Holdings Corporation from July 2015 to January 2018, where he also worked as Vice President of Operations of the SeaSpine business within Integra LifeSciences Corporation from March 2015 to July 2015. From November 2013 until March 2015, he was an industry consultant advising on mergers and acquisitions and providing business process optimization services. He holds a B.A. degree in business from the University of Phoenix. - Brian D. Baker于2022年1月重新加入Dynatronics Corporation，担任首席运营官。Baker先生于2019年8月至2020年7月担任Dynatronics Corporation首席执行官，并于2019年5月至2019年8月担任Dynatronics Corporation首席运营官。因与新冠肺炎病毒相关的健康问题，Baker先生辞去首席执行官一职后，继续担任公司雇员至2020年10月8日，随后担任公司顾问和董事会成员，至2022年1月重新全职加入Dynatronics Corporation。2018年2月至2019年5月，Baker先生担任Dynatronics Corporation治疗产品部总裁。在加入Dynatronics之前，他于2015年7月至2018年1月担任SeaSpine控股公司全球运营副总裁，于2015年3月至2015年7月担任Integra LifeSciences公司Seaspine业务运营副总裁。2013年11月至2015年3月，他担任行业顾问，提供并购和业务流程优化服务。他拥有凤凰城大学商学学士学位。
- Brian D. Baker,was recently appointed as Chief Executive Officer effective October 1, 2023 and as President in May 2023. Mr. Baker first joined the Company as President of Therapy Products in February 2018. He served as Chief Operating Officer from May 2019 until his promotion to Chief Executive Officer in August 2019. Mr. Baker held that position until July 2020, when he resigned due to health issues relating to the COVID-19 virus. Following his resignation as Chief Executive Officer, Mr. Baker continued as a member of the Board and a consultant to the Company until his appointment as Chief Operating Officer in January 2022. Prior to joining the Company, Mr. Baker was Vice President of Global Operations of Seaspine Holdings Corporation from July 2015 to January 2018, where he also worked as Vice President of Operations of the SeaSpine business within Integra LifeSciences Corporation from March 2015 to July 2015. From November 2013 until March 2015, he was an industry consultant advising on mergers and acquisitions and providing business process optimization services. He holds a B.A. degree in business from the University of Phoenix.
- David B. Holtz
-
David B. Holtz，一直担任Provco Group Ltd（Dynatronics公司的优先股股东）的负责人（2012年以来）。他曾任职Provco公司的执行管理集团，负责管理投资组合和会计功能。2011年至2012年，他曾担任Grey Street Holdings（房地产投资控股公司）的执行经理。2008年至2010年，他曾担任Nucryst Pharmaceuticals Corp的首席财务官，随后担任临时总裁。1993年至2006年，他曾任职Integra LifeSciences，担任多种职务，包括财务副总裁、财务主管、高级财务副总裁，以及财务主管。加入Integra公司之前，他曾担任Coopers & Lybrand, L.L.P.（位于费城）、Cono Leasing Corporation（私人租赁公司）的副合伙人。他持有Susquehanna University的工商管理学士学位，也是宾夕法尼亚州注册会计师（直到1998年）。
David B. Holtz,has been a principal of Provco Group Ltd. ("Provco") since 2012. Provco became a preferred shareholder of Dynatronics in 2015. He serves as part of Provco's executive management group responsible for managing investment portfolios and the accounting function. From 2011 to 2012, Mr. Holtz was executive manager of Grey Street Holdings, a property investment holding company. From 2008 to 2010, he served as Chief Financial Officer and then Interim President of Nucryst Pharmaceuticals Corp. From 1993 to 2006, Mr. Holtz worked at Integra LifeSciences in various capacities including Vice President, Finance and Treasurer, and Senior Vice President, Finance and Treasurer. Before joining Integra, Mr. Holtz was an associate with Coopers & Lybrand, L.L.P. in Philadelphia and Cono Leasing Corporation, a private leasing company. He received a B.S. degree in Business Administration from Susquehanna University and was a certified public accountant in Pennsylvania until 1998. - David B. Holtz，一直担任Provco Group Ltd（Dynatronics公司的优先股股东）的负责人（2012年以来）。他曾任职Provco公司的执行管理集团，负责管理投资组合和会计功能。2011年至2012年，他曾担任Grey Street Holdings（房地产投资控股公司）的执行经理。2008年至2010年，他曾担任Nucryst Pharmaceuticals Corp的首席财务官，随后担任临时总裁。1993年至2006年，他曾任职Integra LifeSciences，担任多种职务，包括财务副总裁、财务主管、高级财务副总裁，以及财务主管。加入Integra公司之前，他曾担任Coopers & Lybrand, L.L.P.（位于费城）、Cono Leasing Corporation（私人租赁公司）的副合伙人。他持有Susquehanna University的工商管理学士学位，也是宾夕法尼亚州注册会计师（直到1998年）。
- David B. Holtz,has been a principal of Provco Group Ltd. ("Provco") since 2012. Provco became a preferred shareholder of Dynatronics in 2015. He serves as part of Provco's executive management group responsible for managing investment portfolios and the accounting function. From 2011 to 2012, Mr. Holtz was executive manager of Grey Street Holdings, a property investment holding company. From 2008 to 2010, he served as Chief Financial Officer and then Interim President of Nucryst Pharmaceuticals Corp. From 1993 to 2006, Mr. Holtz worked at Integra LifeSciences in various capacities including Vice President, Finance and Treasurer, and Senior Vice President, Finance and Treasurer. Before joining Integra, Mr. Holtz was an associate with Coopers & Lybrand, L.L.P. in Philadelphia and Cono Leasing Corporation, a private leasing company. He received a B.S. degree in Business Administration from Susquehanna University and was a certified public accountant in Pennsylvania until 1998.
- Brian M. Larkin
-
Brian M. Larkin，一直担任Acelity L.P., Inc的高级副总裁兼总经理，负责再生医学的业务（2015年5月以来）。加入Acelity之前，他曾担任Integra Lifesciences Holdings Corporation的公司副总裁，在那里他曾担任全球脊椎和生物性骨材业务总裁，以及Integra公司的战略开发主管。他的职责包括行政监督和领导Integra的全球脊椎和生物性骨材企业，也负责执行监督Integra公司的几个职能，包括企业营销和战略规划。他于2000年1月加入Integra公司，担任区域销售经理。他于2003年被提拔为国家销售经理，于2005年被提拔为北美销售副总裁，还于2007年被提拔为Integra公司的神经外科的业务总裁。他于2010年被任命为总裁，负责全球脊柱和生物性骨材，以及战略开发主管。加入Integra公司之前，他曾担任Connell Neurosurgical公司的国家销售经理。他持有the University of Richmond的化学学士学位，并完成了Harvard Business School的进阶管理项目。
Brian M. Larkin,is President and CEO of Comar, Inc., a privately held manufacturer of devices and rigid packaging Dynatronics Corporation ed in the medical, pharmaceutical and consumer industries, where he has held the position since April of 2022. From February of 2018 to March of 2022, he served as President and CEO of privately held SP Industries, Inc. From May 2017 to February 2018, he served as the Vice President and General Manager of the Diabetes Care business at Becton Dickinson. From May 2015 to May 2017, he served as Senior Vice President and General Manager for LifeCell, Inc., a Division of Acelity L.P., Inc. Prior to joining Acelity, Mr. Larkin was Corporate Vice President of Integra Lifesciences Holdings Corporation, which he joined in January of 2000 and where he served most recently as President of the Global Spine and Orthobiologics business and Head of Strategic Development. Mr. Larkin received a B.S. degree in Chemistry from the University of Richmond and completed the Advanced Management Program at Harvard Business School. - Brian M. Larkin，一直担任Acelity L.P., Inc的高级副总裁兼总经理，负责再生医学的业务（2015年5月以来）。加入Acelity之前，他曾担任Integra Lifesciences Holdings Corporation的公司副总裁，在那里他曾担任全球脊椎和生物性骨材业务总裁，以及Integra公司的战略开发主管。他的职责包括行政监督和领导Integra的全球脊椎和生物性骨材企业，也负责执行监督Integra公司的几个职能，包括企业营销和战略规划。他于2000年1月加入Integra公司，担任区域销售经理。他于2003年被提拔为国家销售经理，于2005年被提拔为北美销售副总裁，还于2007年被提拔为Integra公司的神经外科的业务总裁。他于2010年被任命为总裁，负责全球脊柱和生物性骨材，以及战略开发主管。加入Integra公司之前，他曾担任Connell Neurosurgical公司的国家销售经理。他持有the University of Richmond的化学学士学位，并完成了Harvard Business School的进阶管理项目。
- Brian M. Larkin,is President and CEO of Comar, Inc., a privately held manufacturer of devices and rigid packaging Dynatronics Corporation ed in the medical, pharmaceutical and consumer industries, where he has held the position since April of 2022. From February of 2018 to March of 2022, he served as President and CEO of privately held SP Industries, Inc. From May 2017 to February 2018, he served as the Vice President and General Manager of the Diabetes Care business at Becton Dickinson. From May 2015 to May 2017, he served as Senior Vice President and General Manager for LifeCell, Inc., a Division of Acelity L.P., Inc. Prior to joining Acelity, Mr. Larkin was Corporate Vice President of Integra Lifesciences Holdings Corporation, which he joined in January of 2000 and where he served most recently as President of the Global Spine and Orthobiologics business and Head of Strategic Development. Mr. Larkin received a B.S. degree in Chemistry from the University of Richmond and completed the Advanced Management Program at Harvard Business School.
- R. Scott Ward
-
R. Scott Ward担任犹他州立大学物理治疗系系主任。他是美国物理治疗协会前任会长，他从2006年到2012年一直任该职位。此外，他担任美国烧伤协会的康复委员会主席。他已出版了伤口护理和烧伤康复相关的广泛的调查研究。他获得犹他州大学物理治疗文学学士学位以及生理学博士学位。
R. Scott Ward,serves as professor in the Department of Physical Therapy at the University of Utah. He is the past president of the American Physical Therapy Association, a position he held from 2006 to 2012. In addition, Dr. Ward served as chair of the rehabilitation committee of the American Burn Association. He has published extensive research studies related to wound care and burn rehabilitation. Dr. Ward received a B.A. degree in Physical Therapy and a Ph.D. degree in Physiology from the University of Utah. - R. Scott Ward担任犹他州立大学物理治疗系系主任。他是美国物理治疗协会前任会长，他从2006年到2012年一直任该职位。此外，他担任美国烧伤协会的康复委员会主席。他已出版了伤口护理和烧伤康复相关的广泛的调查研究。他获得犹他州大学物理治疗文学学士学位以及生理学博士学位。
- R. Scott Ward,serves as professor in the Department of Physical Therapy at the University of Utah. He is the past president of the American Physical Therapy Association, a position he held from 2006 to 2012. In addition, Dr. Ward served as chair of the rehabilitation committee of the American Burn Association. He has published extensive research studies related to wound care and burn rehabilitation. Dr. Ward received a B.A. degree in Physical Therapy and a Ph.D. degree in Physiology from the University of Utah.
高管简历
中英对照 | 中文 | 英文- Brian D. Baker
Brian D. Baker于2022年1月重新加入Dynatronics Corporation，担任首席运营官。Baker先生于2019年8月至2020年7月担任Dynatronics Corporation首席执行官，并于2019年5月至2019年8月担任Dynatronics Corporation首席运营官。因与新冠肺炎病毒相关的健康问题，Baker先生辞去首席执行官一职后，继续担任公司雇员至2020年10月8日，随后担任公司顾问和董事会成员，至2022年1月重新全职加入Dynatronics Corporation。2018年2月至2019年5月，Baker先生担任Dynatronics Corporation治疗产品部总裁。在加入Dynatronics之前，他于2015年7月至2018年1月担任SeaSpine控股公司全球运营副总裁，于2015年3月至2015年7月担任Integra LifeSciences公司Seaspine业务运营副总裁。2013年11月至2015年3月，他担任行业顾问，提供并购和业务流程优化服务。他拥有凤凰城大学商学学士学位。
Brian D. Baker,was recently appointed as Chief Executive Officer effective October 1, 2023 and as President in May 2023. Mr. Baker first joined the Company as President of Therapy Products in February 2018. He served as Chief Operating Officer from May 2019 until his promotion to Chief Executive Officer in August 2019. Mr. Baker held that position until July 2020, when he resigned due to health issues relating to the COVID-19 virus. Following his resignation as Chief Executive Officer, Mr. Baker continued as a member of the Board and a consultant to the Company until his appointment as Chief Operating Officer in January 2022. Prior to joining the Company, Mr. Baker was Vice President of Global Operations of Seaspine Holdings Corporation from July 2015 to January 2018, where he also worked as Vice President of Operations of the SeaSpine business within Integra LifeSciences Corporation from March 2015 to July 2015. From November 2013 until March 2015, he was an industry consultant advising on mergers and acquisitions and providing business process optimization services. He holds a B.A. degree in business from the University of Phoenix.- Brian D. Baker于2022年1月重新加入Dynatronics Corporation，担任首席运营官。Baker先生于2019年8月至2020年7月担任Dynatronics Corporation首席执行官，并于2019年5月至2019年8月担任Dynatronics Corporation首席运营官。因与新冠肺炎病毒相关的健康问题，Baker先生辞去首席执行官一职后，继续担任公司雇员至2020年10月8日，随后担任公司顾问和董事会成员，至2022年1月重新全职加入Dynatronics Corporation。2018年2月至2019年5月，Baker先生担任Dynatronics Corporation治疗产品部总裁。在加入Dynatronics之前，他于2015年7月至2018年1月担任SeaSpine控股公司全球运营副总裁，于2015年3月至2015年7月担任Integra LifeSciences公司Seaspine业务运营副总裁。2013年11月至2015年3月，他担任行业顾问，提供并购和业务流程优化服务。他拥有凤凰城大学商学学士学位。
- Brian D. Baker,was recently appointed as Chief Executive Officer effective October 1, 2023 and as President in May 2023. Mr. Baker first joined the Company as President of Therapy Products in February 2018. He served as Chief Operating Officer from May 2019 until his promotion to Chief Executive Officer in August 2019. Mr. Baker held that position until July 2020, when he resigned due to health issues relating to the COVID-19 virus. Following his resignation as Chief Executive Officer, Mr. Baker continued as a member of the Board and a consultant to the Company until his appointment as Chief Operating Officer in January 2022. Prior to joining the Company, Mr. Baker was Vice President of Global Operations of Seaspine Holdings Corporation from July 2015 to January 2018, where he also worked as Vice President of Operations of the SeaSpine business within Integra LifeSciences Corporation from March 2015 to July 2015. From November 2013 until March 2015, he was an industry consultant advising on mergers and acquisitions and providing business process optimization services. He holds a B.A. degree in business from the University of Phoenix.
- John Krier
John Krier自2020年7月起担任首席执行官。他于2020年3月加入Dynatronics，担任首席财务官，直到被任命为首席执行官。在加入该公司之前，Krier先生是Breg，Inc.（一家重要的Dynatronics客户）市场部的Vice President，他在该公司的工作包括担任Breg’；的支撑产品和技术营销团队的执行领导职务，其中包括与梦百合系统的集成应用、与第三方付款人报销有关的服务解决方案以及客户体验。Krier先生在南达科他州大学（University of South Dakota）获得学士学位。他是一名不活跃的注册会计师，是美国注册会计师协会和明尼苏达注册会计师协会的成员。
John Krier,currently serves as Dynatronics Corporation acting Principal Financial Officer, a position he has held since July 2022. He also served as Dynatronics Corporation President from July 2020 until May 2023 and Chief Executive Officer from July 2020 until his resignation effective October 1, 2023. Prior to his appointment as Chief Executive Officer, he served as Dynatronics Corporation Chief Financial Officer from March 2020 until July 2020. Prior to joining Dynatronics Corporation , Mr. Krier was Vice President of Marketing and Commercial Operations at Breg, Inc., a significant customer of ours, where his work included executive leadership for Breg's bracing product and technology marketing teams, including integrated applications with healthcare systems, service solutions with third-party payer reimbursement, and customer experience. Mr. Krier received a B.S. degree in Business Administration from the University of South Dakota. He is a Certified Public Accountant (inactive), and a member of the American Institute of Certified Public Accountants and Minnesota Society of Public Accountants.- John Krier自2020年7月起担任首席执行官。他于2020年3月加入Dynatronics，担任首席财务官，直到被任命为首席执行官。在加入该公司之前，Krier先生是Breg，Inc.（一家重要的Dynatronics客户）市场部的Vice President，他在该公司的工作包括担任Breg’；的支撑产品和技术营销团队的执行领导职务，其中包括与梦百合系统的集成应用、与第三方付款人报销有关的服务解决方案以及客户体验。Krier先生在南达科他州大学（University of South Dakota）获得学士学位。他是一名不活跃的注册会计师，是美国注册会计师协会和明尼苏达注册会计师协会的成员。
- John Krier,currently serves as Dynatronics Corporation acting Principal Financial Officer, a position he has held since July 2022. He also served as Dynatronics Corporation President from July 2020 until May 2023 and Chief Executive Officer from July 2020 until his resignation effective October 1, 2023. Prior to his appointment as Chief Executive Officer, he served as Dynatronics Corporation Chief Financial Officer from March 2020 until July 2020. Prior to joining Dynatronics Corporation , Mr. Krier was Vice President of Marketing and Commercial Operations at Breg, Inc., a significant customer of ours, where his work included executive leadership for Breg's bracing product and technology marketing teams, including integrated applications with healthcare systems, service solutions with third-party payer reimbursement, and customer experience. Mr. Krier received a B.S. degree in Business Administration from the University of South Dakota. He is a Certified Public Accountant (inactive), and a member of the American Institute of Certified Public Accountants and Minnesota Society of Public Accountants.